YFY Biotech Management Company YFY Biotech Management Company

News

*

Dec 9, 2016

MVC Teamed with US CDC to develop VLP Vaccine for Dengue Disease

Earlier this October, Medigen Vaccine Biologics. Co (MVC) announced a collaboration with US CDC to develop VLP (virus-like-particle) dengue vaccine as 2nd generation product. Combining with the live attenuated dengue vaccine licensed from US NIH, MVC builds robust product portfolio to elicit broader protection to eradicate dengue disease.

VLP is self-assembling envelope or capsid protein mimicking the morphology of native virus without the infectious viral genome, making VLP non-infectious yet able to induce required immune response. Furthermore, VLP technology offers an efficient scaffold to incorporate heterologous antigens, making it a convenient platform to develop multivalent vaccines.

With global warming, emerging mosquito-borne diseases like dengue and Zika have increased over years. Dengue, in particular, has affected most Asian and Latin American countries. WHO estimated there are over 390 million dengue infections every year, with 96 million people manifesting severe dengue symptom.

MVC partners with US CDC to speed up VLP vaccine development by sending scientists to conduct research with US CDC in United States, and transfer the platform back to Hsin-Chu factory for scale-up and process development. Collaborating with CDC will not only introduce latest VLP technology Taiwan, but this platform can be further applied to develop multivalent vaccines against different emerging tropical diseases.




Source:Medigen Biotechnology Corp. 
http://www.medigen.com.tw/en/mvc-teamed-with-us-cdc-to-develop-vlp-vaccine-for-dengue-disease/